A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects.

@article{Gruzdev2003ARD,
  title={A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects.},
  author={Boris Gruzdev and Aza G Rakhmanova and Ekaterina Doubovskaya and Alexey A. Yakovlev and Monika Peeters and Alex Rinehart and Karin de Dier and Patricia Baede-Van Dijk and Wim Van Parys and Gerben van 't Klooster},
  journal={AIDS},
  year={2003},
  volume={17 17},
  pages={2487-94}
}
OBJECTIVE To evaluate antiviral activity, tolerability, safety and pharmacokinetics of treatment with TMC125 (a non-nucleoside reverse transcriptase inhibitor), 900 mg twice daily for 7 days. DESIGN Randomized, double-blind, placebo-controlled, phase IIA clinical trial. SETTING Two hospital clinics in Moscow and St Petersburg, Russian Federation. PARTICIPANTS Nineteen antiretroviral-naive, HIV-1-infected subjects. INTERVENTIONS Randomization (2:1) was to twice daily treatment with… CONTINUE READING
25 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

Similar Papers

Loading similar papers…